Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.
Kellie N SmithNicolas J LlosaTricia R CottrellNicholas SiegelHongni FanPrerna SuriHok Yee ChanHaidan GuoTeniola OkeAnas H AwanFranco VerdeLudmila DanilovaValsamo AnagnostouAda J TamBrandon S LuberBjarne R BartlettLaveet K AulakhJohn-William SidhomQingfeng ZhuCynthia L SearsLeslie CopeWilliam H SharfmanElizabeth D ThompsonJoanne RiemerKristen A MarroneJarushka NaidooVictor E VelculescuPatrick M FordeBert VogelsteinKenneth W KinzlerNickolas PapadopoulosJennifer N DurhamHao WangDung T LeSune JustesenJanis M TaubeLuis A DiazJulie R BrahmerDrew M PardollRobert A AndersFranck HousseauPublished in: Journal for immunotherapy of cancer (2019)
These findings suggest that T cell responses to oncogenic driver mutations may be more prevalent than previously appreciated and could be harnessed in immunotherapeutic treatment, particularly for patients who lack the traditional biomarkers associated with response. Comprehensive studies are warranted to further delineate additional predictive biomarkers and populations of patients who may benefit from checkpoint blockade.